Home › NDC Lookup › RxCUI directory › RxCUI 1988399

Latanoprostene bunod 0.24 MG/ML Ophthalmic Solution [Vyzulta] — RxCUI 1988399

RxNorm drug concept · Semantic branded drug
RxCUI 1988399 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 4 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1988399
Official nameLatanoprostene bunod 0.24 MG/ML Ophthalmic Solution [Vyzulta]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asVyzulta 0.024 % Ophthalmic Solution; Vyzulta 0.24 MG/ML Ophthalmic Solution
FDA products mapped1
Package NDCs mapped4
Reported Medicaid activity (SDUD)13,742 prescriptions · 31 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Latanoprostene Bunod Ophthalmic: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Vyzulta is an eye drop used to lower the pressure inside your eye. It's prescribed for people with open-angle glaucoma or ocular hypertension — a condition where eye pressure is hi...
  • The evening timing is intentional — the pressure-lowering effect peaks about 11 to 13 hours after you use the drop, which lines up with the overnight period. More importantly, you...
  • Why does it need to be used in the evening? Can I use it in the morning instead?
  • Possibly, yes — and this is one of the most important things to know about this medication. Vyzulta can slowly increase brown pigment in the iris (the colored part of your eye), an...
📖 Read our full Latanoprostene Bunod Ophthalmic guide →

🕸️ Concept Web — How Latanoprostene bunod 0.24 MG/ML Ophthalmic Solut... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Latanoprostene bunod 0.24 MG/ML Ophthalmic Solution [Vyzulta] RxCUI 1988399

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Latanoprostene bunod 1988390
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Vyzulta 1988395
  3. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Latanoprostene bunod Ophthalmic Solution 1988393
    • Latanoprostene bunod Ophthalmic Product 1988392
    • Latanoprostene bunod Ophthalmic Solution [Vyzulta] 1988397
    • Vyzulta Ophthalmic Product 1988398
    • Ophthalmic Solution 7670
    • Ophthalmic Product 1151135
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Brand-Name Concepts

  • Latanoprostene bunod 0.24 MG/ML [Vyzulta] SBDC · 1988396
  • Latanoprostene bunod Ophthalmic Solution [Vyzulta] SBDF · 1988397
  • Vyzulta Ophthalmic Product SBDG · 1988398
  • Vyzulta BN · 1988395

📦 FDA Products & Package NDCs

1 product · 4 package NDCs
4 package NDCs map to RxCUI 1988399 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
24208-0504-01 1 BOTTLE in 1 CARTON (24208-504-01) / 2.5 mL in 1 BOTTLE Vyzulta Bausch & Lomb Incorporated 2018-06-11
24208-0504-02 1 BOTTLE in 1 CARTON (24208-504-02) / 2.5 mL in 1 BOTTLE Vyzulta Bausch & Lomb Incorporated 2018-06-11
24208-0504-05 1 BOTTLE in 1 CARTON (24208-504-05) / 5 mL in 1 BOTTLE Vyzulta Bausch & Lomb Incorporated 2017-11-02
24208-0504-06 1 BOTTLE in 1 CARTON (24208-504-06) / 5 mL in 1 BOTTLE Vyzulta Bausch & Lomb Incorporated 2017-11-02
Observed labelers: Bausch & Lomb Incorporated (4) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ml · median
$102.2545
Range $102.2440–$102.2650 · middle 50% $102.2493–$102.2598 · 2 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.